Format

Send to

Choose Destination
See comment in PubMed Commons below
Pediatr Blood Cancer. 2009 Apr;52(4):536-8. doi: 10.1002/pbc.21878.

Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome.

Author information

1
Division of Pediatric Hematology and Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA.

Abstract

Catastrophic antiphospholipid syndrome (CAPS) is a life-threatening condition characterized by small-vessel thrombi and a rapid onset of multiorgan system failure associated with systemic inflammatory response syndrome. Current treatment options include anticoagulants, corticosteroids, plasma exchange, and intravenous immunoglobulin, but these are not always effective. Rituximab, a chimeric anti-CD20 monoclonal antibody, may help eliminate autoreactive B cells and thus limit the rapid inflammatory process involved in CAPS. We describe the use of rituximab in the successful initial management of a probable case of pediatric CAPS.

PMID:
19061212
DOI:
10.1002/pbc.21878
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center